NxStage Announces Access to Demographic and Outcomes Information for the Growing U.S. Daily Home Hemodialysis Patient ...( LAWRENCE Mass. July 23 /- NxStage...)

LAWRENCE, Mass., July 23 /PRNewswire-FirstCall/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced ongoing public access to current summary information derived from a registry of NxStage patients with end-stage renal-disease (ESRD) who undergo hemodialysis at home on a more frequent, or daily, basis as an alternative to the conventional regimen of therapy received three times a week at a dialysis center.

This unique, quantitative portrait of key characteristics of ESRD patients who have been receiving daily home hemodialysis, which includes correlation with survival and kidney transplant relative to that observed with conventional hemodialysis, reflects more than a thousand patient years of experience and more than one million treatments. This is believed to be the largest known database of home hemodialysis patients.

Key statistics from the registry, which are available on the NxStage web site (http://www.nxstage.com/chronic_renal_care/registry/), include the following:

-- Survival and transplant rates are notably higher among the NxStage patient population undergoing daily therapy vs. reported figures for conventional, less frequent dialysis treatment. NxStage patients on home daily hemodialysis experienced a better than 50% reduction in expected mortality compared to the overall U.S. hemodialysis patient population. This observed difference was statistically significant (P<0.0001).

-- Patients of varied size, age, vascular access type, and geographic location are participating in home daily hemodialysis, indicating its broad applicability.

-- 92% of the U.S. dia
'/>"/>